Through its discovery platform, Octagon has identified a rate-limiting enzyme involved in central metabolism that drives the rapid proliferation of disease-causing cells. This target has been evaluated in resistant bacterial infection and holds significant potential for the development of a new antibiotic class.
A potent inhibitor of this enzyme, OTG005, has shown a high level of effectiveness in animal infection models of resistant Pseudomonas aeruginosa and Acinetobacter baumanii. The medicine has been previously shown to be well tolerated in patients. Octagon is currently optimizing this lead compound for antibiotic activity.
Effectiveness in Animal Models
OTG005 has demonstrated compelling effectiveness against infections caused by Acinetobacter and Pseudomonas in animal models and has previously been shown to be safe in humans. Octagon is exploring the potential of this medicine to address resistant pulmonary infections in patients with Cystic Fibrosis.